

CURRICULUM VITAE

July 2014

Tatiana Baron

North Shore Diabetes & Endocrine Associates
3003 New Hyde Park Road
Suite 201
New Hyde Park, New York 11042
(516) 327-0850
tbaron@nsdea.com

Professional Experience

7/2012 to present **North Shore Diabetes and Endocrine Associates**

7/2008 – 6/2009 **Chief Resident, Internal Medicine Residency Program**
Winthrop University Hospital, Mineola NY

Training

7/2009- **Endocrinology fellowship Program**
Winthrop University Hospital, Mineola, NY

7/2005 – 6/2008 **Internal Medicine Residency Program**
Winthrop University Hospital, Mineola, NY

Education

8/2000 – 5/2005 **D.O., New York college of Osteopathic Medicine**
Old Westbury, NY

- PSI SIGMA ALPHA HONOR SOCIETY

8/1997 – 1/2000 **B.A., New York University, College of Arts and Sciences**
New York, NY

- Biology Major
- CUM LAUDE
- Founders Day Award

9/1991 – 6/1995 **Medical Student, Moscow Medical Academy**
Moscow Russian Federation

- Honor Student

T. Baron
7/9/14

Licensure and Certifications

10/4/2011	American Board of Internal Medicine Certification in Endocrinology, Diabetes and Metabolism
8/2009	ACLS Certification
10/2008	New York State Medical License # 2580931
8/2008	American Board of Internal Medicine certification

Professional Memberships

9/2010 – Present	American Association of Clinical Endocrinologists
3/2004	PSI SIGMA ALPHA HONOR SOCIETY
2/2011 - Present	Endocrine Society

Presentations

4/2010	Winthrop University Hospital House Staff Research Day Poster "Multiorgan effects of Pheochromocytoma"
3/2004	Long Island Clinical Endocrinology Society Meeting

Research Experience

11/2010 - 2011	Sub-Investigatory: EFC11319 : A randomized, double-blind, placebo-controlled, parallel group multicenter study to evaluate cardiovascular outcomes during treatment with Lixisenatide in type 2 diabetic patients after an acute coronary syndrome. Winthrop University Hospital, Mineola, NY
10/2010 - 2011	Sub-Investigatory: MKC-TI-162 : A phase 3b, Multicenter, Open-Label, Randomized, Forced-titration, Clinical Trial Evaluating the Efficacy and Safety of Technosphere Insulin Inhalation Powder, Using the Gen2 Inhaler, in combination with Insulin Glargine vs. Insulin Aspart in Combination with Insulin Glargine in Subject with Type 2 Diabetes Mellitus over a 16 week treatment Period. Winthrop University Hospital Mineola, NY
10/2010 - 2011	Sub-Investigatory: MKC-TI-164 : A Phase 3b, Multicenter, Clinical Trial to Evaluate Pulmonary Function in s a subset of subjects with Type 1 or Type 2 Diabetes Enrolled in 1 of 3 Parent Trails. Winthrop University Hospital, Mineola, NY
11/2010 - 2011	Sub- Investigator: EAGLE : A randomized, parallel-group, open-label, comparative study of insulin Glargine vs. liraglutide in insulin-naïve patients with type 2 diabetes treated with oral agents and not adequately controlled. Winthrop University Hospital, Mineola, NY
9/2006 – 4/2010	Sub-Investigatory: "Glycemic Variability Predicts Endothelial dysfunction" clinical trial Department of Endocrinology Winthrop University Hospital Mineola, NY
10/2006 – 4/2007	Sub-Investigatory: "Vitamin D Supplementation for Cold and Flu Prevention" clinical trial Bone Mineral Research Center

Research Studies

Sub Investigator- Oral Diabetic Agent- AstraZeneca
Sub Investigator-Oral Diabetic Agent- Johnson & Johnson
Sub Investigator- Inhaled insulin (2 studies type I and Type II)
Sub Investigator- Oral Diabetic Agent- Boehringer Ingelheim
Sub Investigator- Oral Diabetic Agent/High Cardiovascular Risk- AstraZeneca
Sub Investigator- Insulin Delivery System-Valeritas
Sub Investigator- Insulin-Eli Lilly
Sub Investigator- Growth Hormone – Lilly
Sub Investigator- Nephropathy-Abbott
Sub Investigator-Insulin for Type 1 Diabetics- Lilly
Sub Investigator-Insulin for Type 2 Diabetics- Lilly
Sub Investigator-Insulin for Type 1 Diabetics- Sanofi
Sub Investigator-Insulin for Type 2 Diabetics- Sanofi
Sub Investigator-Injectable Diabetic Medication- Sanofi
Sub Investigator-Injectable medication for Hyperlipidemia- Amgen
Sub Investigator-Oral Diabetic Agent- BristolMyers
Sub Investigator-infusible medication for insulin pump- Halozyme Therapeutics
Sub Investigator-Diabetic Nephropathy-AbbVie
Sub Investigator- MACE assessment of an Oral Diabetic Agent- AstraZeneca
Sub Investigator-Injectable Diabetic Medication-Sanofi
Sub Investigator-Injectable Diabetic Medication- Sanofi